Company Overview
Snapshot
Founded in April 2015 by Jacob Zankel and Prof. Sandu Pitaru, Cytora operates with 11–50 employees. The company has raised $2M across two funding rounds from two investors. In May 2026, Cytora appointed Dr. Thomas Serena, a renowned wound care expert, to its Scientific Advisory Board to advance patient treatment access and data collection for its hOMSC therapy.
Business overview
Cytora is a clinical-stage biotechnology company focused on developing allogeneic stem cell therapies derived from human oral mucosa stem cells (hOMSC). The company aims to establish hOMSC as a standard treatment for severe diseases, including Parkinson’s, Multiple System Atrophy (MSA), Alzheimer’s Dementia, and non-healing diabetic wounds. As a portfolio company of Galil Ofek Innovations, Cytora operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceutical and life sciences markets with its cell therapy solutions.
Strategic signal
In May 2026, Cytora appointed Dr. Thomas Serena, a world-renowned wound care expert, to its Scientific Advisory Board. This strategic addition is poised to significantly accelerate patient treatment access and data collection for Cytora's human oral mucosa stem cell (hOMSC) therapy, signaling a strong push towards clinical validation and market penetration in the regenerative medicine space.
Log in to access full profile ›Company Intelligence Q&A
- What is Cytora's primary focus?
- Cytora is a clinical-stage biotechnology company developing allogeneic stem cell therapies from human oral mucosa stem cells (hOMSC) for treating severe diseases such as Parkinson’s, Alzheimer’s Dementia, and non-healing diabetic wounds.
- When was Cytora founded and by whom?
- Cytora was founded in April 2015 by Jacob Zankel and Prof. Sandu Pitaru.
- What significant appointment did Cytora make in May 2026?
- In May 2026, Cytora appointed Dr. Thomas Serena, a world-renowned wound care expert, to its Scientific Advisory Board to lead patient treatment access and data collection for its hOMSC therapy.
- What were the results of Cytora's Phase 1/2a trial for diabetic foot ulcers?
- In April 2025, Cytora reported successful results from its Phase 1/2a trial of stem cell treatment for diabetic foot ulcers.